{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-019249","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.849339+00:00","generated_at":"2026-06-25T13:45:31.396896+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galectin Therapeutics Q1 net loss $9.9M ($0.17/shr); cash runway through May 2023","bullets":["Net loss of $9.9M for Q1 2022 vs $6.3M in Q1 2021; R&D spend rose to $8.1M (up from $4.9M) on NAVIGATE trial costs.","Cash and equivalents $31.6M; company expects to fund operations through at least May 16, 2023.","Expects to require additional $40-45M to reach planned interim analysis of NAVIGATE trial in mid-2024.","Phase 2b/3 NAVIGATE trial enrollment for NASH cirrhosis on track to finish Phase 2b portion around Q3 2022.","Company preparing IND to study belapectin in combination with Keytruda for recurrent head and neck cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-019249","json":"https://secwatch.observer/filing/0001140361-22-019249.json","markdown":"https://secwatch.observer/filing/0001140361-22-019249.md","text":"https://secwatch.observer/filing/0001140361-22-019249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122019249/0001140361-22-019249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122019249/brhc10037527_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T13:45:31.396896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"992501f5a0cfb423aa0c3c537809487265e135b6","claim":"GALECTIN THERAPEUTICS INC reported the three months ended March 31, 2022 results: net income net loss applicable to common stockholders of $9.9 million, EPS ($0.17) per share.","evidence_excerpt":"For the three months ended March 31, 2022, the Company reported a net loss applicable to common stockholders of $9.9 million, or ($0.17) per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122019249/0001140361-22-019249-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2022"},{"label":"Net income","value":"net loss applicable to common stockholders of $9.9 million"},{"label":"EPS","value":"($0.17) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}